This is an extended access study for participants who have completed Rufinamide Study E2080-G000-303 to continue to have access to rufinamide until it becomes commercially available in Poland or until no participants remain in the EAP.
Drug: Rufinamide
Rufinamide up to 45 milligram per kilogram per day (mg/kg/day).
Inclusion Criteria:
- Participants who were on rufinamide treatment and have completed Study E2080-G000-303
in Poland.
Exclusion Criteria:
- Participants were randomized to the other antiepileptic drug (AED) treatment group in
study E2080-G000-303.
Generała Tadeusza Kościuszki 52
Kielce, Poland
Szpital Kliniczny im. Heliodora Święcickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu
Poznań, Poland
Eisai Medical Information
1-888-274-2378
esi_medinfo@eisai.com